 Once-daily aminoglycoside therapy once-daily administration aminoglycosides attractive concept animal experiments clinical trials reduction influence risk toxicity Less frequent dosing contact time host tissue sites drug Thanks PAE as-yet-unrecognized factors fall level serum MIC antibacterial efficacy fact peak level serum drug efficacy dosage interval neutropenic patients vivo PAE small-colony variants PAE concomitant beta-lactam time data clinical trials United available results international trials encouraging potential benefit patients reasonable infectious diseases consultants educational process necessary once-daily aminoglycoside therapy institutions